Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 20;16(3):e56560.
doi: 10.7759/cureus.56560. eCollection 2024 Mar.

Comparison of the Effectiveness and Safety of Metoprolol and Diltiazem in Atrial Fibrillation With Rapid Ventricular Rate Patients: A Systematic Review and Meta-Analysis

Abshiro H Mayow  1 , Tanya Sinha  2 , Mansoor Ahmad  3 , Ye Kyaw Myint  4 , Samyuktha Balaji  5 , Sandipkumar S Chaudhari  6   7 , Divine Besong Arrey Agbor  8 , Areeba Khan  9
Affiliations
Review

Comparison of the Effectiveness and Safety of Metoprolol and Diltiazem in Atrial Fibrillation With Rapid Ventricular Rate Patients: A Systematic Review and Meta-Analysis

Abshiro H Mayow et al. Cureus. .

Abstract

This study aims to assess the association between intravenous diltiazem and metoprolol in rate control for atrial fibrillation (AF) patients with rapid ventricular rate, focusing on rate control efficacy and hemodynamic adverse events. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, electronic searches were conducted in Embase, PubMed, and Cochrane Central Register of Controlled Trials (CENTRAL) until February 20, 2024. The primary outcome was achieving ventricular rate control < 110/min. Secondary outcomes included new hypotension (systolic blood pressure < 90 mm Hg) and bradycardia (heart rate < 60/min). Nineteen studies (three randomized controlled trials and 16 observational studies) were included in this meta-analysis. Pooled analysis showed intravenous metoprolol resulted in a 39% lower rate control attainment compared to diltiazem (OR: 0.61; 95% CI: 0.44 to 0.84; p = 0.002). There were no significant differences in bradycardia (OR: 0.51; 95% CI: 0.22 to 1.22; p = 0.13) or hypotension risk (OR: 1.08; 95% CI: 0.72 to 1.61; p = 0.72) between the two groups. Intravenous diltiazem demonstrated superior rate control efficacy compared to metoprolol in AF patients with rapid ventricular rate. However, no significant differences were observed in safety outcomes, namely, bradycardia and hypotension.

Keywords: atrial fibrillation; diltiazem; meta-analysis; metoprolol; rate control.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. PRISMA flowchart of study selection
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Figure 2
Figure 2. Comparison of achievement of rate control target
Sources: References [10-27].
Figure 3
Figure 3. Comparison of risk of bradycardia
Sources: References [9,10,13-15,20-22].
Figure 4
Figure 4. Comparison of risk of hypotension
Sources: References [9,10,12-17,19-22,24,27].
Figure 5
Figure 5. Comparison of achievement of rate control target in patients with HFrEF
HFrEF: heart failure with reduced ejection fraction. Sources: References [10,18,19,21].
See this image and copyright information in PMC

References

    1. Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. Walkey AJ, Wiener RS, Ghobrial JM, Curtis LH, Benjamin EJ. JAMA. 2011;306:2248–2254. - PMC - PubMed
    1. Atrial fibrillation among Medicare beneficiaries hospitalized with sepsis: incidence and risk factors. Walkey AJ, Greiner MA, Heckbert SR, et al. Am Heart J. 2013;165:949–955. - PMC - PubMed
    1. Emergency department, hospital inpatient, and mortality burden of atrial fibrillation in the United States, 2006 to 2014. Jackson SL, Tong X, Yin X, George MG, Ritchey MD. Am J Cardiol. 2017;120:1966–1973. - PMC - PubMed
    1. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Stewart S, Hart CL, Hole DJ, McMurray JJV. Am J Med. 2002;113:359–364. - PubMed
    1. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. January CT, Wann LS, Alpert JS, et al. J Am Coll Cardiol. 2014;64:0–76. - PubMed

LinkOut - more resources